Merck's groundbreaking treatment, Keytruda (pembrolizumab), has made a major breakthrough in the fight against high-risk locally advanced cervical cancer. The ...
On March 11, 2024, Moderna Inc. (MRNA) saw its stock close at $113.22, following an opening price of $103.44. Throughout ...
On March 11, 2024, Merck & Co (NYSE:MRK) received a significant downgrade from Societe Generale analyst Justin Smith, who shifted ...
Moderna and Merck Join Forces in Groundbreaking Skin Cancer Treatment Trial March 11, 2024 Moderna and Merck have teamed up ...
On January 31, 2024, Merck & Co (NYSE:MRK) is set to unveil its quarterly earnings report on February 1, 2024. ...
On January 29, 2024, the Phase 3 KEYNOTE-564 trial conducted by Merck investigated the effectiveness of Keytruda as an adjuvant ...
On January 27, 2024, groundbreaking news emerged in the field of urothelial carcinoma treatment. Merck's revolutionary drug, KEYTRUDA (pembrolizumab), has ...
